STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Rhea-AI Summary
Akouos, Inc., a subsidiary of Eli Lilly and Company, announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, demonstrating hearing restoration within 30 days of AK-OTOF administration in the first participant with profound hearing loss. The study focuses on AK-OTOF gene therapy for OTOF-mediated hearing loss due to mutations in the otoferlin gene. The results will be presented at the 2024 Association for Research in Otolaryngology MidWinter Meeting. The initial participant, an 11-year-old with profound hearing loss from birth, experienced restored hearing across all tested frequencies, achieving thresholds within the normal hearing range at some frequencies. The therapy was well tolerated with no serious adverse events reported. AK-OTOF has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA and has received a positive opinion on orphan drug designation by the EMA Committee for Orphan Medicinal Products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial
-
News
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) is set to announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. The company will conduct a conference call to provide detailed information to the investment community and media. The conference call will be accessible through a live webcast on Lilly's website, with a replay available afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
earnings
-
News
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) introduces LillyDirect™, a digital healthcare experience for patients in the U.S. living with obesity, migraine, and diabetes. The platform offers disease management resources, access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
News
Lilly to Participate in J.P. Morgan Healthcare Conference
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will participate in the 42nd Annual J.P. Morgan Healthcare Conference, with CEO David A. Ricks joining a fireside chat on Jan. 9 at 5:15 p.m. Eastern time. A live audio webcast and replay will be available on Lilly's Investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
conferences
-
News
Lilly Completes Acquisition of POINT Biopharma
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) successfully completed the acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies for cancer treatment. The acquisition was completed through a tender offer and a second-step merger. Lilly acquired approximately 67.97% of POINT's outstanding shares. The acquisition marks Lilly's entry into the next-generation radioligand therapies space, with the goal of bringing new radioligand therapies to cancer patients to improve their outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
acquisition
-
News
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
Rhea-AI Summary
Eli Lilly and Company (LLY) extends the expiration of the tender offer to acquire all shares of POINT Biopharma Global Inc. (PNT) at $12.50 per share in cash. The offer has been extended until Dec. 22, 2023, to fulfill the minimum tender condition. Approximately 22.81% of the issued and outstanding shares have been tendered as of Dec. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
acquisition
News
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) presents updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, at the 65th ASH Annual Meeting and Exposition. The data supports the potential role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
clinical trial
-
News
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
Rhea-AI Summary
Lilly's Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, as published in The Journal of the American Medical Association. The study showed Zepbound led to sustained weight loss compared to placebo, with a mean weight reduction of 20.9% at 36 weeks and a mean weight regain of 14.8% at 88 weeks for the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
News
Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) increases quarterly dividend by 15% to $1.30 per share for the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
dividends
News
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
Rhea-AI Summary
Eli Lilly and Company (LLY) announced results from the MONARCH 3 clinical trial, showing a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor. The OS outcomes were not statistically significant. Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant (oral SERD) in combination with Verzenio, will be presented at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#9 Ranked by Market Cap
#348 Ranked by Stock Gains
#1940 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.